Drug-Resistant Malaria: The Era of ACT
- 379 Downloads
As drug-resistant falciparum malaria has continued to evolve and spread worldwide, artemisinin-based combination therapies (ACT) have become the centerpiece of global malaria control over the past decade. This review discusses how advances in antimalarial drug resistance monitoring and rational use of the array of ACTs now available can maximize the impact of this highly efficacious therapy, even as resistance to artemisinins is emerging in Southeast Asia.
KeywordsDrug-resistant malaria Artemisinin-based combination therapy ACT Plasmodium falciparum Antimalarial resistance
No potential conflict of interest relevant to this article was reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Trape JF: The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 2001, 64:127.Google Scholar
- 2.World Health Organization: Methods for Surveillance of Antimalarial Drug Efficacy. Geneva: World Health Organization; 2009.Google Scholar
- 13.World Health Organization: Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006.Google Scholar
- 16.Ringwald, Pascal: Susceptibility of Plasmodium falciparum to antimalarial drugs: report on global monitoring 1996–2004. Geneva: World Health Organization; 2005.Google Scholar
- 17.World Health Organization: Antimalarial drug combination therapy: report of a WHO technical consultation, 4–5 April 2001. Geneva: World Health Organization; 2001.Google Scholar
- 18.World Health Organization: World Malaria Report 2008. Geneva: World Health Organization; 2008. Google Scholar
- 19.World Health Organization: World Malaria Report 2009. Geneva: World Health Organization, 2009.Google Scholar
- 20.World Health Organization: Facts on ACTs. January 2006 Update. Available at http://rbm.who.int/cmc_upload/0/000/015/364/RBMInfosheet_9.htm. Accessed February 2010.
- 21.World Health Organization: Country antimalarial drug policies: by region. Available at http://www.who.int/malaria/am_drug_policies_by_region_afro/en/index.html. Accessed February 2010.
- 23.Sutherland C, Drakeley CJ, Obisike U, et al.: The addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children delays, but does not prevent treatment failure. Am J Trop Hyg 2003, 69:19–25.Google Scholar
- 24.Sinclair D, Zani B, Donegan S, et al.: Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009, CD007483.Google Scholar
- 33.Abdulla S, Sagara I, Borrmann S, et al.: Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008, 372:1819–1827.CrossRefPubMedGoogle Scholar
- 34.Olliaro P, Mussano P: Amodiaquine for treating malaria. Cochrane Database Syst Rev 2003, CD000016.Google Scholar
- 40.• Newton PN, Fernández FM, Plançon A, et al.: A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008, 5:e32. This article provides an eye-opening account of widespread counterfeit activities that are threatening efforts to contain artemisinin resistance.CrossRefPubMedGoogle Scholar
- 41.Bukirwa H, Critchley J: Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiquine for treating uncomplicated malaria. Cochrane Database Syst Rev 2006:CD004966.Google Scholar
- 44.World Health Organization: Global malaria control and elimination: report of a meeting on containment of artemisinin tolerance. Geneva: World Health Organization 2008.Google Scholar
- 45.• Wongsrichanalai C, Meshnick SR: Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 2008, 14:716–719. This article summarizes the earliest evidence of artesunate-mefloquine failure on the Cambodian-Thai border and provides a critical discussion of possible factors contributing to the development of ACT resistance.CrossRefPubMedGoogle Scholar
- 46.Vijaykadga S, Alker AP, Tongkong D, et al.: Delayed P. falciparum parasite clearance following artesunate-mefloquine combination therapy in Thailand, 1997–2007 [abstract 1119]. Presented at the American Society of Tropical Medicine and Hygiene 57th Annual Meeting. New Orleans, LA, USA; December 7–11, 2008.Google Scholar
- 47.Lim P, Wongsrichanalai C, Chim P, et al.: Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrob Agents Chemother 2010, 54(5). doi: 10.1128/AAC.01304-09.
- 48.•• Dondorp AM, Nosten F, Yi Po, et al.: Artemisinin Resistance in Plasmodium falciparum Malaria. N Eng J Med 2009, 361:455–467. This article presents the first evidence of significant artemisinin resistance in western Cambodia based on an artemisinin monotherapy trial, thus supporting earlier observations of artesunate-mefloquine failure.CrossRefGoogle Scholar
- 50.Se Y, Lon C, Socheat D, et al.: Effects of increasing artesunate dose in seven-day monotherapy regimens on treatment response in Cambodian patients with uncomplicated falciparum malaria [abstract 22]. Presented at the American Society of Tropical Medicine and Hygiene 58th Annual Meeting. Washington, DC, USA; November 18–22, 2009.Google Scholar
- 51.Bethell D, Se Y, Lon C, et al.: Dose-dependent risk of neutropenia following seven-day courses of artesunate monotherapy in adult Cambodian patients with acute falciparum malaria [abstract 858]. Presented at the American Society of Tropical Medicine and Hygiene 58th Annual Meeting. Washington, DC, USA; November 18–22, 2009.Google Scholar
- 55.• Olliaro P, Wells TN: The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 2009, 85:584–595. This article provides a comprehensive review of new antimalarials in the clinical and preclinical phases of development and their potential impact on malaria control and elimination.CrossRefPubMedGoogle Scholar